Ignite Creation Date:
2025-12-25 @ 12:13 AM
Ignite Modification Date:
2025-12-25 @ 10:15 PM
Study NCT ID:
NCT06092658
Status:
COMPLETED
Last Update Posted:
2023-10-23
First Post:
2023-08-21
Is NOT Gene Therapy:
False
Has Adverse Events:
False
Brief Title:
Cohort Study of Chronic Heart Failure
Sponsor:
Xiang Xie
Organization:
Study Overview
Official Title:
Cohort Study of Chronic Heart Failure
Status:
COMPLETED
Status Verified Date:
2023-10
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose is to understand the clinical characteristics of chronic heart failure as soon as possible, analyze the etiology, comorbidities, clinical characteristics, and treatment of heart failure patients, observe the gap between real-world clinical practice and guideline recommendations, and provide reference for the improvement of heart failure prevention and treatment in China.
Detailed Description:
Inclusion criteria:
1. Accompanied by difficulty breathing, fatigue, or decreased activity tolerance;
2. Signs of fluid retention (pulmonary congestion and peripheral edema);
3. Echocardiography shows abnormalities in cardiac structure and/or function;
4. Elevated levels of natriuretic peptide: B-type natriuretic peptide (BNP)\>35 ng/L and/or N-terminal B-type proBNP (NT proBNP)\>125 ng/L.
5. HF hospitalization recorded within the previous 12 months
Exclusion criteria:
1. Concomitant severe liver function, renal failure, or other severe system dysfunction
2. Poor compliance, inability to obtain information, or voluntary refusal to participate in this study.
1. Accompanied by difficulty breathing, fatigue, or decreased activity tolerance;
2. Signs of fluid retention (pulmonary congestion and peripheral edema);
3. Echocardiography shows abnormalities in cardiac structure and/or function;
4. Elevated levels of natriuretic peptide: B-type natriuretic peptide (BNP)\>35 ng/L and/or N-terminal B-type proBNP (NT proBNP)\>125 ng/L.
5. HF hospitalization recorded within the previous 12 months
Exclusion criteria:
1. Concomitant severe liver function, renal failure, or other severe system dysfunction
2. Poor compliance, inability to obtain information, or voluntary refusal to participate in this study.
Study Oversight
Has Oversight DMC:
False
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?: